APS:CA:TSX-Aptose Biosciences Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 6.41

Change

0.00 (0.00)%

Market Cap

CAD 0.57B

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

N/A

CAD1.97B N/A N/A
TRIL:CA Trillium Therapeutics Inc

N/A

CAD1.29B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
BLU:CA BELLUS Health Inc

N/A

CAD0.45B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

N/A

CAD0.26B 5.40 N/A
IMV:CA IMV Inc

N/A

CAD0.23B -99,999.99 N/A
FRX:CA Fennec Pharmaceuticals Inc

N/A

CAD0.21B 30.20 N/A
RVX:CA Resverlogix Corp

N/A

CAD0.21B 63.57 26.37
ATE:CA Antibe Therapeutics Inc

N/A

CAD0.20B N/A N/A
ONC:CA Oncolytics Biotech Inc

N/A

CAD0.20B N/A N/A

ETFs Containing APS:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.67% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.67% 61% D- 69% D+
Trailing 12 Months  
Capital Gain -42.56% 16% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.56% 16% F 1% F
Trailing 5 Years  
Capital Gain 97.84% 58% F 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.84% 58% F 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 70.11% 74% C 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.11% 74% C 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 111.47% 32% F 5% F
Risk Adjusted Return 62.90% 79% C+ 77% C+
Market Capitalization 0.57B 90% A- 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.83 82% B- 27% F
Price / Cash Flow Ratio -16.81 65% D 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -51.91% 80% B- 11% F
Return on Invested Capital -52.40% 50% F 4% F
Return on Assets -30.75% 75% C 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.74 15% F 18% F
Short Percent 0.59% 43% F 92% A-
Beta 1.30 47% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector